The potential of combining ziftomenib with intensive chemotherapy in newly diagnosed AML

Adding Menin Inhibitors in Combination Therapy for AML Patients | Amir Fathi, MD | #ASH24Подробнее

Menin Inhibitor Study Results: Ziftomenib for Newly Diagnosed AML Patients | Amer Zeidan | #ASH24Подробнее

Gilteritinib combined with induction and consolidation chemotherapy in newly diagnosed AML patientsПодробнее

The KOMET-007 trial: ziftomenib plus intensive chemotherapy to treat AMLПодробнее

Courtney DiNardo, MD, considers the role of intensive chemotherapy in newly diagnosed AMLПодробнее

Adding Venetoclax to 7+3 Chemotherapy in Newly Diagnosed AML | Ioannis Mantzaris, MD | #ASH24Подробнее

Assessing purine-analog-based intensive chemotherapy combined with venetoclax for ND and R/R AMLПодробнее

The KOMET-007 trial: investigating combinations with ziftomenib in newly diagnosed and R/R AMLПодробнее

KOMET-008: a Phase I trial of ziftomenib combinations in KMT2A-rearranged or NPM1-mutant AMLПодробнее

The frontline treatment strategy for newly diagnosed AMLПодробнее

Acute Myeloid Leukemia: Novel Therapies for Newly Diagnosed Patients - Part 2Подробнее

Combining Azacitadine/Enasidenib to Enhance the Treatment of Newly Diagnosed IDH2-Mutant AMLПодробнее

Novel Therapies in Myeloid NeoplasmsПодробнее

Combination AML Therapy for Newly Diagnosed Patients | What Are the Long-Term Effects?Подробнее

Role of CPX-351 in Acute Myeloid LeukemiaПодробнее

Dr. Lai on the Potential Benefits of Venetoclax in AMLПодробнее

Phase I study of ziftomenib with venetoclax or venetoclax/azacitidine or 7+3 in R/R AMLПодробнее

Upcoming clinical trials for venetoclax chemotherapy combinations for AMLПодробнее

Prof. Keith Pratz | ASH 2017 | Gilteritinib & intensive chemotherapy in newly diagnosed FLT3+ AMLПодробнее